Hartmann et al. investigated the prognostic relevance of four prominent molecular markers in WHO grade II gliomas, including TP53 mutation, 1p/19q deletion, O6-methylguanylmethyltransferase (MGMT) promoter methylation, and isocitrate dehydrogenase 1 (IDH1) mutation. This evidence concerns the gene IDH1 and central nervous system cancer.